Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Article content
BEIJING — In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement:
Article content
Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute.
Article content
120 vs. 9 – A Significant Technical Divide of RenNano® Platform
Article content
;
Article content
Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights
Article content
The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms.
Article content
The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase.
Article content
Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence.
Article content
We remain confident in:
Article content
The technical integrity and legal foundation of the RenNano® platform;
The non-infringement of any third-party IP;
Our continued leadership in antibody discovery and therapeutic innovation.
Article content
According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients.
Article content
Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery.
Article content
Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform
Article content
Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire.
Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches.
Article content
About Biocytogen
Article content
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Article content
Article content
Article content
Contacts
Article content
Biocytogen Contacts
Article content
Article content
Antibody platform and assets:
Article content
BD-Licensing@biocytogen.com
Article content
Article content
Preclinical models and services:
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Why Gold ETFs Are Rallying in 2025 – Geopolitical Risks & Central Bank Strategies
Geopolitical Turmoil Sends Gold to New Highs Gold is once again proving its safe-haven strength, trading firmly above $3,420 per ounce as conflicts in the Middle East escalate. With central bank decisions looming and potential U.S. policy shifts on the horizon, investors are turning to gold, not just as a short-term hedge, but as a long-term store of value. Central Banks Double Down on Gold According to the European Central Bank, gold now accounts for 20% of global official reserves—its highest share in decades, even overtaking the euro. This shift is being led by emerging markets like China, India, and Turkey, which are actively reducing their exposure to dollar-based financial systems and mitigating geopolitical risk. This wave of institutional demand is creating a durable floor for gold, supporting prices even during periods of relative market calm. Gold Demand Broadens Amid Policy and Market Risks Beyond geopolitics, gold's appeal is growing on multiple fronts. With the Federal Reserve hinting at rate cuts and the potential return of U.S. tariffs under renewed political leadership, investors are leaning on gold for more than just inflation protection. Today, gold plays multiple roles: A hedge against currency volatility A buffer against financial system shocks A neutral reserve in a fractured global trade landscape Together, these forces suggest gold's momentum isn't just reactionary—it may be structural, marking its return as a strategic portfolio cornerstone. Canadian Gold ETFs Deliver Strong Returns The bullish environment has propelled Canadian gold-focused ETFs to standout performance in 2024: Top Performers (YTD): Global X Gold Producers ETF (GLDX): +62.7% iShares Global Gold ETF (XGD): +52.8% BMO Junior Gold ETF (ZJG): +51.9% Bullion ETFs Show Steady Gains: iShares Gold Bullion ETF (CGL): +30.0% BMO Gold Bullion ETF (ZGLD): +24.3% Recent weekly performance remains strong, with GLDX and XGD gaining over 4% as tensions persist. This consistent outperformance across both miner and bullion ETFs demonstrates gold's broad-based strength in current markets. Group Data Funds Specific Data
Globe and Mail
2 hours ago
- Globe and Mail
Intel Stock (NASDAQ:INTC) Blasts Up as Mac Support Dies
New reports probably should have been worse for chip stock Intel (INTC) than they turned out to be, as they noted that the age of Intel processors in Apple (AAPL) Mac computers was coming to an end. But Intel shareholders treated this revelation like a grand celebration, and sent shares blasting up over 8% in Tuesday afternoon's trading. Confident Investing Starts Here: The reports noted that MacOS Tahoe will be the last version of MacOS to offer support for Macs that use Intel processors. This includes several older MacBook Pro, iMac and Mac Pro models, and those who have these computers will still be able to enjoy the updates made available with the launch of Tahoe later on. However, there is one caveat: Apple Intelligence will not be made available to those computers. Apple Intelligence requires Apple processors to run, reports note. The loss of Apple as a customer for some desktop hardware was not exactly unexpected. Apple has been working to migrate from Intel to its own processors for the last five years, reports noted, but Apple promised to support Intel processors '…for years to come.' Five years later, that promise seems to have been kept, and is reaching its end accordingly. Brighter Days So what in the world sent Intel rocketing up? There was some good news out for Intel along with the bad news. The entire chip sector got something of a boost from talks with China in the trade field, giving Intel a bit of a 'halo effect' boost. Reports noted that '…hopes that the talks between the U.S. and China will result in looser export restrictions' helped fuel Intel's impressive gains today. And, Intel also benefited from moves at the Department of Defense, which says that the DoD is likely to offer up '…operational technology-specific zero trust guidance,' according to Intel's federal chief technology officer. The move will provide guidance on specific cybersecurity protections to implement in a bid to maintain military systems, including things like weapons systems, sensor arrays, and shipyard systems, among others. Is Intel a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on INTC stock based on one Buy, 26 Holds and four Sells assigned in the past three months, as indicated by the graphic below. After a 33.76% loss in its share price over the past year, the average INTC price target of $21.29 per share implies 3.88% downside risk. See more INTC analyst ratings Disclosure Disclaimer & Disclosure Report an Issue
Globe and Mail
4 hours ago
- Globe and Mail
BABA Down 8% in a Month: Will Partnership With Apple Aid Recovery?
Alibaba Group 's BABA shares have lost 8.2% over the past month, underperforming the Zacks Internet-Commerce industry and the Zacks Retail-Wholesale sector, thus reflecting investor uncertainty despite progress in the company's AI partnership with Apple. The Chinese e-commerce and cloud computing giant recently released versions of its Qwen3 AI models for Apple's MLX architecture, enabling compatibility with iPhones, iPads, MacBooks, and Mac computers. This development represents a significant step toward bringing Apple Intelligence features to the Chinese market, though regulatory headwinds continue to cloud the partnership's future. 1-Month Performance Apple Partnership Advances Amid Regulatory Scrutiny The technical integration of Alibaba's AI models with Apple devices marks meaningful progress in their collaboration to deliver AI-powered features to Chinese consumers. Apple Intelligence encompasses various AI tools, including Genmoji and Writing Tools, which require local partnership to comply with Chinese regulations. The partnership has gained strategic importance as Apple's iPhone sales captured the top position in China during May, with global sales rising 15% year over year in April and May according to Counterpoint Research data. However, the collaboration faces mounting pressure from U.S. officials who have been scrutinizing the arrangement. Reports indicate that White House and congressional officials are examining Apple's plans to integrate Alibaba's AI technology into iPhones sold in China, reflecting broader tensions in U.S.-China technology relations. This scrutiny introduces uncertainty about the partnership's timeline and ultimate implementation, potentially affecting both companies' strategic plans in the crucial Chinese market. Mixed Quarterly Performance Reflects Broader Challenges Alibaba's fourth-quarter fiscal 2025 results presented a mixed picture that disappointed investors. Total revenues reached RMB 236.5 billion, representing 7% year-over-year growth, though this figure missed the Zacks Consensus Estimate by 1.49%. The company's adjusted EBITA showed stronger performance with 36% year-over-year growth to RMB 32.6 billion, indicating operational efficiency improvements. The Taobao and Tmall Group demonstrated resilience with customer management revenues growing 12% year over year, primarily driven by improved take rates. Meanwhile, the Cloud Intelligence Group accelerated growth to 18% year over year, with AI-related product revenues maintaining triple-digit growth for the seventh consecutive quarter. This cloud performance underscores the potential value of the Apple partnership, though regulatory uncertainties may limit near-term benefits. However, various business segments showed mixed results, with some areas like Cainiao Smart Logistics experiencing revenue declines due to operational restructuring. The Zacks Consensus Estimate for fiscal 2026 earnings indicates a downward revision of 1.5% over the past 60 days to $10.62 per share, the market appears to be pessimistic about Alibaba's growth trajectory. See the Zacks Earnings Calendar to stay ahead of market-making news. Regulatory Risks Create Strategic Uncertainty The regulatory environment presents the most significant risk to Alibaba's growth trajectory, particularly regarding the Apple partnership. U.S. resistance toward the Apple-Alibaba AI arrangement could limit cloud revenue upside potential. This uncertainty may prompt Alibaba to delay research investments and capital spending on related infrastructure until clearer regulatory guidance emerges. The company's expansion beyond China continues through partnerships like the recent GoTo Group collaboration in Indonesia, where Alibaba Cloud successfully migrated GoTo Financial's infrastructure. Such international ventures provide diversification opportunities, though they cannot fully offset challenges in core markets. Valuation and Competitive Landscape Despite recent declines, Alibaba's valuation metrics suggest the stock trades at a significant discount compared to global technology peers. The stock's forward 12-month Price/Earnings ratio of 10.61X, as compared to the Zacks Internet-Commerce industry average of 24.05X, remains compressed due to ongoing regulatory concerns and slower growth expectations. This valuation gap reflects market skepticism about Chinese technology stocks generally, though it also presents potential upside for patient investors. BABA's P/E F12M Ratio Depicts Discounted Valuation Competition in China's e-commerce and cloud markets continues intensifying. Domestic rivals like JD and Pinduoduo maintain pressure on e-commerce operations, while international cloud providers like Microsoft MSFT and Amazon AMZN compete for enterprise customers. However, Alibaba's market leadership position and AI capabilities provide defensive advantages, particularly in cloud computing, where technical expertise creates meaningful barriers to entry. The company's financial position remains robust with RMB 366.4 billion in net cash, providing flexibility for strategic investments and shareholder returns. During fiscal 2025, Alibaba repurchased $11.9 billion in shares and announced $4.6 billion in dividends, demonstrating a commitment to shareholder value creation. Investment Outlook: Patience Required Given current uncertainties surrounding the Apple partnership and broader regulatory environment, investors should consider maintaining existing positions while avoiding significant new investments until greater clarity emerges. The technical progress with Apple integration suggests long-term potential, but regulatory risks could delay meaningful benefits into fiscal 2026. The stock's compressed valuation provides downside protection for current holders, while the company's strong cash position and improving operational metrics support a patient approach. Investors seeking new positions might benefit from waiting for the resolution of regulatory uncertainties or more attractive entry points that could emerge if partnership delays materialize. BABA stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Inc. (JD): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report
